Preclinical analysis of MTOR complex 1/2 inhibition in diffuse intrinsic pontine glioma

Flannery,Patrick C.; DeSisto,John A.; Amani,Vladimir; Venkataraman,Sujatha; Lemma,Rakeb T.; Prince,Eric W.; Donson,Andrew; Moroze,Erin E.; Hoffman,Lindsey; Levy,Jean M. Mulcahy; Foreman,Nicholas; Vibhakar,Rajeev; Green,Adam L.

doi:10.3892/or.2017.6122

Preclinical analysis of MTOR complex 1/2 inhibition in diffuse intrinsic pontine glioma

Authors:
- Patrick C. Flannery
- John A. DeSisto
- Vladimir Amani
- Sujatha Venkataraman
- Rakeb T. Lemma
- Eric W. Prince
- Andrew Donson
- Erin E. Moroze
- Lindsey Hoffman
- Jean M. Mulcahy Levy
- Nicholas Foreman
- Rajeev Vibhakar
- Adam L. Green
View Affiliations

Affiliations: Morgan Adams Foundation Pediatric Brain Tumor Research Program, University of Colorado School of Medicine, Aurora, CO 80045, USA
Published online on: November 29, 2017 https://doi.org/10.3892/or.2017.6122
Pages: 455-464
Copyright: © Flannery et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Diffuse intrinsic pontine glioma (DIPG) is an incurable childhood brain tumor. The mechanistic target of rapamycin (MTOR), a key oncogene, functions as two distinct signaling complexes, MTORC1 and MTORC2. We set out to determine the preclinical efficacy and mechanism of action of MTOR inhibitors in DIPG. We evaluated the MTORC1 inhibitor everolimus and the MTORC1/2 inhibitor AZD2014 in three patient-derived DIPG cell lines using cell culture models. We created dose-response curves for both compounds. We measured phenotypic effects on cell self-renewal, apoptosis, cell cycle, differentiation, senescence, and autophagy. We assessed the effects of each compound on the AKT pathway. Finally, we measured the efficacy of AZD2014 in combination with radiation therapy (RT) and a panel of FDA-approved chemotherapy drugs. While everolimus showed minimal antitumor efficacy, AZD2014 revealed IC50 levels of 410-552 nM and IC90 levels of 1.30-8.86 µM in the three cell lines. AZD2014 demonstrated increased inhibition of cell self-renewal compared to everolimus. AZD2014 decreased expression of phospho-AKT, while no such effect was noted with everolimus. Direct AKT inhibition showed similar efficacy to AZD2014, and induction of constitutive AKT activity rescued DIPG cells from the effects of AZD2014. AZD2014 exhibited synergistic relationships with both RT and various chemotherapy agents across classes, including the multikinase inhibitor ponatinib. MTORC1/2 inhibition shows antitumor activity in cell culture models of DIPG due to the effect of MTORC2 inhibition on AKT. This strategy should be further assessed for potential incorporation into combinatorial approaches to the treatment of DIPG.

View Figures

View References

1	Fangusaro J: Pediatric high-grade gliomas and diffuse intrinsic pontine gliomas. J Child Neurol. 24:1409–1417. 2009. View Article : Google Scholar : PubMed/NCBI
2	Massimino M, Spreafico F, Biassoni V, Simonetti F, Riva D, Trecate G, Giombini S, Poggi G, Pecori E, Pignoli E, et al: Diffuse pontine gliomas in children: Changing strategies, changing results? A mono-institutional 20-year experience. J Neurooncol. 87:355–361. 2008. View Article : Google Scholar : PubMed/NCBI
3	Green AL and Kieran MW: Pediatric brainstem gliomas: New understanding leads to potential new treatments for two very different tumors. Curr Oncol Rep. 17:4362015. View Article : Google Scholar : PubMed/NCBI
4	Hashizume R, Ozawa T, Gryaznov SM, Bollen AW, Lamborn KR, Frey WH II and Deen DF: New therapeutic approach for brain tumors: Intranasal delivery of telomerase inhibitor GRN163. Neuro-oncol. 10:112–120. 2008. View Article : Google Scholar : PubMed/NCBI
5	Goodwin CR, Xu R, Iyer R, Sankey EW, Liu A, Abu-Bonsrah N, Sarabia-Estrada R, Frazier JL, Sciubba DM and Jallo GI: Local delivery methods of therapeutic agents in the treatment of diffuse intrinsic brainstem gliomas. Clin Neurol Neurosurg. 142:120–127. 2016. View Article : Google Scholar : PubMed/NCBI
6	Barua NU, Lowis SP, Woolley M, O'Sullivan S, Harrison R and Gill SS: Robot-guided convection-enhanced delivery of carboplatin for advanced brainstem glioma. Acta Neurochir (Wien). 155:1459–1465. 2013. View Article : Google Scholar : PubMed/NCBI
7	Cohen K, Jones A, Raabe E and Pearl M: Highly selective intra-arterial chemotherapy for the treatment of progressive diffuse intrinsic pontine gliomas (DIPG). In: 20th International Conference on Brain Tumor Research and Therapy Neuro-Oncology, Lake Tahoe, CA. Neurooncology. 16:iii292014.
8	Zeng Z, Sarbassov D, Samudio IJ, Yee KW, Munsell MF, Ellen Jackson C, Giles FJ, Sabatini DM, Andreeff M and Konopleva M: Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML. Blood. 109:3509–3512. 2007. View Article : Google Scholar : PubMed/NCBI
9	Guertin DA, Stevens DM, Thoreen CC, Burds AA, Kalaany NY, Moffat J, Brown M, Fitzgerald KJ and Sabatini DM: Ablation in mice of the mTORC components raptor, rictor, or mlST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCalpha, but not S6K1. Dev Cell. 11:859–871. 2006. View Article : Google Scholar : PubMed/NCBI
10	Guertin DA and Sabatini DM: Defining the role of mTOR in cancer. Cancer Cell. 12:9–22. 2007. View Article : Google Scholar : PubMed/NCBI
11	Akhavan D, Cloughesy TF and Mischel PS: mTOR signaling in glioblastoma: Lessons learned from bench to bedside. Neuro-oncol. 12:882–889. 2010. View Article : Google Scholar : PubMed/NCBI
12	Galanis E, Buckner JC, Maurer MJ, Kreisberg JI, Ballman K, Boni J, Peralba JM, Jenkins RB, Dakhil SR, Morton RF, et al North Central Cancer Treatment Group, : Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: A North Central Cancer Treatment Group Study. J Clin Oncol. 23:5294–5304. 2005. View Article : Google Scholar : PubMed/NCBI
13	Kahn J, Hayman TJ, Jamal M, Rath BH, Kramp T, Camphausen K and Tofilon PJ: The mTORC1/mTORC2 inhibitor AZD2014 enhances the radiosensitivity of glioblastoma stem-like cells. Neuro-oncol. 16:29–37. 2014. View Article : Google Scholar : PubMed/NCBI
14	Schwartzentruber J, Korshunov A, Liu XY, Jones DT, Pfaff E, Jacob K, Sturm D, Fontebasso AM, Quang DA, Tönjes M, et al: Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature. 482:226–231. 2012. View Article : Google Scholar : PubMed/NCBI
15	Buczkowicz P, Hoeman C, Rakopoulos P, Pajovic S, Letourneau L, Dzamba M, Morrison A, Lewis P, Bouffet E, Bartels U, et al: Genomic analysis of diffuse intrinsic pontine gliomas identifies three molecular subgroups and recurrent activating ACVR1 mutations. Nat Genet. 46:451–456. 2014. View Article : Google Scholar : PubMed/NCBI
16	Mehta S, Huillard E, Kesari S, Maire CL, Golebiowski D, Harrington EP, Alberta JA, Kane MF, Theisen M, Ligon KL, et al: The central nervous system-restricted transcription factor Olig2 opposes p53 responses to genotoxic damage in neural progenitors and malignant glioma. Cancer Cell. 19:359–371. 2011. View Article : Google Scholar : PubMed/NCBI
17	Nagaraja S, Vitanza NA, Woo PJ, Taylor KR, Liu F, Zhang L, Li M, Meng W, Ponnuswami A, Sun W, et al: Transcriptional dependencies in diffuse intrinsic pontine glioma. Cancer Cell. 31:635–652 e636. 2017. View Article : Google Scholar : PubMed/NCBI
18	Rodrik-Outmezguine VS, Chandarlapaty S, Pagano NC, Poulikakos PI, Scaltriti M, Moskatel E, Baselga J, Guichard S and Rosen N: mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling. Cancer Discov. 1:248–259. 2011. View Article : Google Scholar : PubMed/NCBI
19	Chou TC: Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 70:440–446. 2010. View Article : Google Scholar : PubMed/NCBI
20	Bahena-Ocampo I, Espinosa M, Ceballos-Cancino G, Lizarraga F, Campos-Arroyo D, Schwarz A, Garcia-Lopez P, Maldonado V and Melendez-Zajgla J: miR-10b expression in breast cancer stem cells supports self-renewal through negative PTEN regulation and sustained AKT activation. EMBO Rep. 17:10812016. View Article : Google Scholar : PubMed/NCBI
21	Lin Y, Yang Y, Li W, Chen Q, Li J, Pan X, Zhou L, Liu C, Chen C, He J, et al: Reciprocal regulation of Akt and Oct4 promotes the self-renewal and survival of embryonal carcinoma cells. Mol Cell. 48:627–640. 2012. View Article : Google Scholar : PubMed/NCBI
22	Singh S, Trevino J, Bora-Singhal N, Coppola D, Haura E, Altiok S and Chellappan SP: EGFR/Src/Akt signaling modulates Sox2 expression and self-renewal of stem-like side-population cells in non-small cell lung cancer. Mol Cancer. 11:732012. View Article : Google Scholar : PubMed/NCBI
23	Paugh BS, Broniscer A, Qu C, Miller CP, Zhang J, Tatevossian RG, Olson JM, Geyer JR, Chi SN, da Silva NS, et al: Genome-wide analyses identify recurrent amplifications of receptor tyrosine kinases and cell-cycle regulatory genes in diffuse intrinsic pontine glioma. J Clin Oncol. 29:3999–4006. 2011. View Article : Google Scholar : PubMed/NCBI
24	Halvorson KG, Barton KL, Schroeder K, Misuraca KL, Hoeman C, Chung A, Crabtree DM, Cordero FJ, Singh R, Spasojevic I, et al: A high-throughput in vitro drug screen in a genetically engineered mouse model of diffuse intrinsic pontine glioma identifies BMS-754807 as a promising therapeutic agent. PLoS One. 10:e01189262015. View Article : Google Scholar : PubMed/NCBI
25	Fontanilla HP, Pinnix CC, Ketonen LM, Woo SY, Vats TS, Rytting ME, Wolff JE and Mahajan A: Palliative reirradiation for progressive diffuse intrinsic pontine glioma. Am J Clin Oncol. 35:51–57. 2012. View Article : Google Scholar : PubMed/NCBI
26	Wolff JE, Rytting ME, Vats TS, Zage PE, Ater JL, Woo S, Kuttesch J, Ketonen L and Mahajan A: Treatment of recurrent diffuse intrinsic pontine glioma: The MD Anderson Cancer Center experience. J Neurooncol. 106:391–397. 2012. View Article : Google Scholar : PubMed/NCBI
27	Frankfurt O and Licht JD: Ponatinib - a step forward in overcoming resistance in chronic myeloid leukemia. Clin Cancer Res. 19:5828–5834. 2013. View Article : Google Scholar : PubMed/NCBI
28	Jansen MH, van Vuurden DG, Vandertop WP and Kaspers GJ: Diffuse intrinsic pontine gliomas: A systematic update on clinical trials and biology. Cancer Treat Rev. 38:27–35. 2012. View Article : Google Scholar : PubMed/NCBI
29	Kim DH, Kwak Y, Kim ND and Sim T: Antitumor effects and molecular mechanisms of ponatinib on endometrial cancer cells harboring activating FGFR2 mutations. Cancer Biol Ther. 17:65–78. 2016. View Article : Google Scholar : PubMed/NCBI
30	Miyahara H, Yadavilli S, Natsumeda M, Rubens JA, Rodgers L, Kambhampati M, Taylor IC, Kaur H, Asnaghi L, Eberhart CG, et al: The dual mTOR kinase inhibitor TAK228 inhibits tumorigenicity and enhances radiosensitization in diffuse intrinsic pontine glioma. Cancer Lett. 400:110–116. 2017. View Article : Google Scholar : PubMed/NCBI